UB Paderborn / Katalog / Suche / in CDI

86 Evaluating BMS-777607 as a candidate therapeutic agent in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S30-S30

2013

Link zum Volltext

Verfügbarkeit prüfen

2: Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S1-S1

2015

Link zum Volltext

Verfügbarkeit prüfen

7 Cancer stem cells: targeting aldehyde dehydrogenase 1 (ALDH1) as a novel strategy to overcome cisplatin resistance in NSCLC

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S3-S3

2016

Link zum Volltext

Verfügbarkeit prüfen

8 Exploitation of the vitamin A/retinoic acid axis in the re-sensitisation of cisplatin resistant NSCLC cells

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S3-S4

2016

Link zum Volltext

Verfügbarkeit prüfen

7: Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S4-S4

2017

Link zum Volltext

Verfügbarkeit prüfen

211 Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S78-S78

2014

Link zum Volltext

Verfügbarkeit prüfen

2 p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S1-S1

2014

Link zum Volltext

Verfügbarkeit prüfen

5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S2-S2

2015

Link zum Volltext

Verfügbarkeit prüfen

8 PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S3-S3

2013

Link zum Volltext

Verfügbarkeit prüfen

7 Targeting neuropilin-1 in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S3-S3

2013

Link zum Volltext

Verfügbarkeit prüfen

6 Circulating tumour cells in NSCLC. Enumeration and analysis using VitaAssay and Screencell techniques

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S2-S3

2013

Link zum Volltext

Verfügbarkeit prüfen

4 Identification and targeting of the DNA repair gene, XRCC6BP1, in cisplatin resistant NSCLC

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S2-S2

2016

Link zum Volltext

Verfügbarkeit prüfen

6 Cisplatin induces the emergence and expansion of a distinct cancer stem cell (CSC) population in NSCLC

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S3-S3

2016

Link zum Volltext

Verfügbarkeit prüfen

2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S1-S2

2017

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR -Mutation Positive ( EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S41-S41

2014

Link zum Volltext

Verfügbarkeit prüfen

1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer

Annals of oncology, 2022-09, Vol.33, p.S1017

2022

Link zum Volltext

Verfügbarkeit prüfen

80 Epigenetic readers and writers as therapeutic targets in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S30-S30

2014

Link zum Volltext

Verfügbarkeit prüfen

5 MicroRNA profiling and characterisation of putative cancer stem cells in cisplatin resistant NSCLC

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S2-S3

2014

Link zum Volltext

Verfügbarkeit prüfen

4 Inhibition of PARP activity by PJ34 sensitises NSCLC cells to cisplatin

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S2-S2

2014

Link zum Volltext

Verfügbarkeit prüfen

10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S4-S4

2014

Link zum Volltext

Verfügbarkeit prüfen

4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S2-S2

2015

Link zum Volltext

Verfügbarkeit prüfen

16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer

Annals of oncology, 2021-12, Vol.32, p.S1380

2021

Link zum Volltext

Verfügbarkeit prüfen

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S25-S25

2016

Link zum Volltext

Verfügbarkeit prüfen

5 A novel microRNA signature associated with cisplatin resistant NSCLC holds both diagnostic and prognostic biomarker potential

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S2-S3

2016

Link zum Volltext

Verfügbarkeit prüfen

56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S26-S26

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

86 Evaluating BMS-777607 as a candidate therapeutic agent in malignant pleural mesothelioma

2: Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer

7 Cancer stem cells: targeting aldehyde dehydrogenase 1 (ALDH1) as a novel strategy to overcome cisplatin resistance in NSCLC

8 Exploitation of the vitamin A/retinoic acid axis in the re-sensitisation of cisplatin resistant NSCLC cells

7: Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system

211 Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study

2 p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells

5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines

8 PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC

7 Targeting neuropilin-1 in non-small cell lung cancer

6 Circulating tumour cells in NSCLC. Enumeration and analysis using VitaAssay and Screencell techniques

4 Identification and targeting of the DNA repair gene, XRCC6BP1, in cisplatin resistant NSCLC

6 Cisplatin induces the emergence and expansion of a distinct cancer stem cell (CSC) population in NSCLC

2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells

Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR -Mutation Positive ( EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)

1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer

80 Epigenetic readers and writers as therapeutic targets in malignant pleural mesothelioma

5 MicroRNA profiling and characterisation of putative cancer stem cells in cisplatin resistant NSCLC

4 Inhibition of PARP activity by PJ34 sensitises NSCLC cells to cisplatin

10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980

4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer

16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

5 A novel microRNA signature associated with cisplatin resistant NSCLC holds both diagnostic and prognostic biomarker potential

56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma

Suchergebnisse filtern